316 related articles for article (PubMed ID: 19105350)
41. Atypical squamous cells of undetermined significance: analysis of microbiology, cytological criteria and clinical conduct.
Barcelos AC; Adad SJ; Michelin MA; Murta EF
Tumori; 2006; 92(3):213-8. PubMed ID: 16869238
[TBL] [Abstract][Full Text] [Related]
42. ASC-US and high-risk HPV testing: performance in daily clinical practice.
Selvaggi SM
Diagn Cytopathol; 2006 Nov; 34(11):731-3. PubMed ID: 17041955
[TBL] [Abstract][Full Text] [Related]
43. [Comparison of efficacy of combined use of liquid cytology and immunohistochemical assay of p16ink4 and standard procedure and high risk evaluation by polymerase chain reaction of human papillomavirus infection in diagnosing cervical dysplasia and carcinoma].
Raskin GA; Petrov SV; Orlova RV; Mal'tseva LI; Akhmetzianova AV; Farrakhova LN; Khasanov RSh
Vopr Onkol; 2009; 55(2):192-5. PubMed ID: 19514374
[TBL] [Abstract][Full Text] [Related]
44. MALDI imaging as a specific diagnostic tool for routine cervical cytology specimens.
Schwamborn K; Krieg RC; Uhlig S; Ikenberg H; Wellmann A
Int J Mol Med; 2011 Mar; 27(3):417-21. PubMed ID: 21174066
[TBL] [Abstract][Full Text] [Related]
45. [HPV test for quality control of gynecologic cytological tests].
Wilander E; Wikström I
Lakartidningen; 2008 Nov 26-Dec 9; 105(48-49):3560, 3564. PubMed ID: 19133586
[No Abstract] [Full Text] [Related]
46. Outcomes of women with atypical squamous cells of undetermined significance and high-risk human papillomavirus DNA.
Feng J; Husain M
Acta Cytol; 2007; 51(5):730-4. PubMed ID: 17910342
[TBL] [Abstract][Full Text] [Related]
47. [Controversial categories in cytopathology of the uterine cervix. I. ASCUS: atypical squamous cells of undetermined significance].
Cenci M; Chieppa A; Vecchione A
Minerva Ginecol; 2001 Feb; 53(1):49-55. PubMed ID: 11279396
[TBL] [Abstract][Full Text] [Related]
48. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
[TBL] [Abstract][Full Text] [Related]
49. Assessing the role of education in women's knowledge and acceptance of adjunct high-risk human Papillomavirus testing for cervical cancer screening.
Papa D; Moore Simas TA; Reynolds M; Melnitsky H
J Low Genit Tract Dis; 2009 Apr; 13(2):66-71. PubMed ID: 19387125
[TBL] [Abstract][Full Text] [Related]
50. [Prognostic value of human papilloma virus DNA test in patients surgically treated for squamous cell cervical cancer].
Bakhidze EV; Lavrinovich OE; Chepik OF; Kiselev OI
Vopr Onkol; 2012; 58(2):233-7. PubMed ID: 22774530
[TBL] [Abstract][Full Text] [Related]
51. Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study.
Zhao C; Li Z; Nayar R; Levi AW; Winkler BA; Moriarty AT; Barkan GA; Rao J; Miller F; Fan F; Zhou Z; Si Q; Fischer AH; Sturgis CD; Jing X; Marshall CB; Witt BL; Birdsong GG; Crothers BA
Arch Pathol Lab Med; 2015 Feb; 139(2):184-8. PubMed ID: 24694342
[TBL] [Abstract][Full Text] [Related]
52. AgNOR technique could be useful for differential diagnosis of squamous carcinomatous cells and atypical cells related to human papillomavirus in cervical smears.
Palaoro L; Rocher A
Biotech Histochem; 2009 Jun; 84(3):73-8. PubMed ID: 19333799
[TBL] [Abstract][Full Text] [Related]
53. [Applicative aspects of liquid-based cytology in cervical cancer screening].
Liverani M; De Paola F; Danesi S; Fedriga R; Dalbuoni V; Agnoletti R; Amadori AR; Mirra F; Bonoli W; Saragoni L
Pathologica; 2006 Dec; 98(6):629-34. PubMed ID: 17285839
[TBL] [Abstract][Full Text] [Related]
54. [ASC-H lesions: diagnostic difficulties in gynecologic cytopathology].
Noël JC
Ann Pathol; 2009 Nov; 29 Spec No 1():S108. PubMed ID: 19887235
[No Abstract] [Full Text] [Related]
55. [Evaluation of genotyping of human papilomavirus by a new DNA liquid chip based on Luminex XMAP].
Deng XM; Liu M; Zheng GX; Wang CX; Zhang J; Li W
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):476-8. PubMed ID: 20718362
[TBL] [Abstract][Full Text] [Related]
56. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.
Ronco G; Brezzi S; Carozzi F; Dalla Palma P; Giorgi-Rossi P; Minucci D; Naldoni C; Segnan N; Zappa M; Zorzi M; Cuzick J;
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S230-2. PubMed ID: 17822751
[TBL] [Abstract][Full Text] [Related]
57. The use of reflex high-risk human papillomavirus testing for atypical squamous cells of undetermined significance interpretations on vaginal specimens.
Kendall BS; Zahn CM
Cancer; 2009 Feb; 117(1):27-31. PubMed ID: 19347826
[TBL] [Abstract][Full Text] [Related]
58. Expression of HPV L1 capsid protein in cervical specimens with HPV infection.
Lee H; Lee KJ; Jung CK; Hong JH; Lee YS; Choi YJ; Lee KY; Park G
Diagn Cytopathol; 2008 Dec; 36(12):864-7. PubMed ID: 18855883
[TBL] [Abstract][Full Text] [Related]
59. [Intraepithelial cervical squamous lesions: comparison between PAP-test, colposcopy, phase contrast microscopy and histology; usefulness of their synergic use].
Iuspa F; Maruotti G; Del Bianco A; Di Martino A; Celeste T; Pietropaolo F
Minerva Ginecol; 2005 Apr; 57(2):153-7. PubMed ID: 15940075
[TBL] [Abstract][Full Text] [Related]
60. Molecular HPV typing as a diagnostic tool to discriminate primary from metastatic squamous cell carcinoma of the lung.
Weichert W; Schewe C; Denkert C; Morawietz L; Dietel M; Petersen I
Am J Surg Pathol; 2009 Apr; 33(4):513-20. PubMed ID: 19145203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
